{"preliminary_commentary":{"by_channel":{"x_thread":70,"youtube":33,"podcast":20,"bluesky_thread":3,"x_video":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05301842\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"EMERALD-3","nct_id":"NCT05301842","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=emerald-3-nct05301842. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"EMERALD-3","arms":[{"description":"Tremelimumab, Durvalumab and Lenvatinib in combination with Transarterial Chemoembolization (TACE)","label":"Arm A","type":"EXPERIMENTAL"},{"description":"Tremelimumab and Durvalumab in combination with Transarterial Chemoemobolization (TACE)","label":"Arm B","type":"EXPERIMENTAL"},{"description":"Transarterial Chemoembolization (TACE)","label":"Arm C","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2027-02-26","type":"ESTIMATED"},"conditions":["Hepatocellular Carcinoma"],"enrollment":{"count":760,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Tremelimumab","otherNames":["MEDI1123"],"type":"DRUG"},{"name":"Durvalumab","otherNames":["MEDI4736"],"type":"DRUG"},{"name":"Transarterial Chemoembolization (TACE)","otherNames":["DEB-TACE and cTACE"],"type":"PROCEDURE"},{"name":"Lenvatinib","otherNames":["Lenvima"],"type":"DRUG"}],"last_update":"2026-10-16","lead_sponsor":"AstraZeneca","official_title":"A Phase III, Randomized, Open-Label, Sponsor-Blinded, Multicenter Study of Durvalumab in Combination With Tremelimumab ± Lenvatinib Given Concurrently With TACE Compared to TACE Alone in Patients With Locoregional Hepatocellular Carcinoma (EMERALD-3)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2026-02-23","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression Free Survival (PFS) for Arm A vs Arm C","timeFrame":"Approximately 5 years"}],"references":[{"citation":"Kudo M, Abou-Alfa GK, Ren Z, Heo J, Lencioni R, Arai Y, Bouattour M, Gonzalez-Carmona MA, Guo Y, Xu AB, Alves GV, Dechaphunkul A, Ho GF, Lim YN, Hu H, Liu R, Gu S, Ostwal V, Manasirisuk W, Chiu CF, Tekumalla SH, Shroff M, Dave V, Rahma O, Erinjeri JP, Fan J; EMERALD-3 Investigators. Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study. Lancet Oncol. 2026 Sep;27(9):1077-1093. doi: 10.1016/S1470-2045(26)00278-0.","pmid":"42636832","type":"DERIVED"}],"start_date":{"date":"2022-03-28","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC","url":"https://clinicaltrials.gov/study/NCT05301842"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/emerald-3-nct05301842"}